Media stories about Pacific Biosciences of California (NASDAQ:PACB) have been trending positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a coverage optimism score of 0.35 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.9887343192039 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Pacific Biosciences of California, Inc. (PACB) Downgraded by First Analysis to Equal Weight (americanbankingnews.com)
- BRIEF-Pacific Biosciences Of California reports Q3 revenue $23.5 mln (reuters.com)
- Pacific Biosciences Appoints Kathy Ordonez As Chief Commercial Officer (thestreet.com)
- Pacific Biosciences Appoints Kathy Ordoñez as Chief Commercial Officer (finance.yahoo.com)
- Pacific Biosciences reports 3Q loss (finance.yahoo.com)
Pacific Biosciences of California (NASDAQ PACB) traded down $1.00 during midday trading on Friday, hitting $3.03. The company’s stock had a trading volume of 4,093,725 shares, compared to its average volume of 639,279. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.24 and a current ratio of 3.72.
Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.01. The business had revenue of $23.54 million during the quarter, compared to analyst estimates of $28.29 million. Pacific Biosciences of California had a negative return on equity of 100.62% and a negative net margin of 95.97%. The company’s revenue was down 6.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.19) EPS. equities research analysts expect that Pacific Biosciences of California will post -0.89 earnings per share for the current fiscal year.
A number of analysts have commented on PACB shares. CL King cut Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price target for the company. in a research report on Thursday, September 28th. BidaskClub lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 27th. First Analysis lowered Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 price objective for the company. in a research note on Friday. Finally, Zacks Investment Research lowered Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $6.27.
TRADEMARK VIOLATION WARNING: This news story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/05/pacific-biosciences-of-california-pacb-getting-positive-news-coverage-accern-reports.html.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.
What are top analysts saying about Pacific Biosciences of California Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pacific Biosciences of California Inc. and related companies.